Clinical trials: Early Stage Triple Negative Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC)…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT05812807
- Testing
- Pembrolizumab, Patient Observation, Biopsy
- Where
- 846 sites in United States, Canada and 1 more
- Volunteers
- 1,295 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Triple Negative Breast Cancer
Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
The purpose of this study is to increase survival of patients with early and locally advanced triple-negative breast cancer adding selumatinib to standard preoperative chemotherapy regimen.
- Trial name
- NCT02685657
- Testing
- Drug: Selumetinib, Doxorubicin, Cyclophosphamide
- Volunteers
- 164 people
- Sponsor
- Russian Academy of Medical Sciences
Breast Cancer, Triple Negative Breast Neoplasms
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
This is a multicenter, prospective, randomized, open-label phase II study evaluating the efficacy and safety of PO→EC as neoadjuvant treatment of operable and locally advanced breast cancer in patients with HR deficiency.
- Conditions
- Breast Cancer, Triple Negative Breast Neoplasms, HRpos Breast Neoplasms, BRCA 1 /2 and / or HRD
- Trial name
- GeparOla (NCT02789332)
- Testing
- PwO, PwCb, EC
- Where
- 12 sites in Germany
- Volunteers
- 107 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer, Triple Negative Breast Cancer (TNBC)
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
To evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer
- Conditions
- Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
- Trial name
- NCT06768931
- Testing
- Biolosion (oral probiotic compound preparation)
- Where
- 5 sites in China
- Volunteers
- 192 people
- Sponsor
- Sun Yat-sen University
Triple-Negative Breast Cancer
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a special type of breast cancer, endocrine therapy and targeted therapy are completely ineffective, chemotherapy is currently the only effective treatment.
- Trial name
- LANCET (NCT03243838)
- Testing
- Apatinib
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Guangdong Provincial People's Hospital
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
This clinical trial studies how well ultrasound/photoacoustic/elasticity (US/PA/E) imaging works for early identification of tumor response in patients with stage II-III triple-negative breast cancer receiving immunotherapy and…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07862751
- Testing
- Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Breast Neoplasms
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
This study aims to evaluate the efficacy and safety of camrelizumab in combination with capecitabine compared to placebo in combination with capecitabine as adjuvant therapy for patients with triple-negative breast cancer (TNBC)…
- Trial name
- NCT06313463
- Testing
- Carrellizumab + Capecitabine
- Where
- China
- Volunteers
- 375 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Triple Negative Breast Cancer
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
The study hypothesise that the combination of carboplatin, gemcitabine, bevacizumab and atezolizumab may be synergistic and improve outcomes for patients with early relapsed TNBC by overcoming mechanisms of immune resistance and…
- Trial name
- BELLA (NCT04739670)
- Testing
- Atezolizumab, Bevacizumab, Gemcitabine
- Where
- 4 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on…
- Trial name
- NeoTILs (NCT07743190)
- Testing
- Carboplatin, Paclitaxcel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Triple Negative Breast Cancer, Premenopausal Breast Cancer
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
Breast cancer (BC), especially premenopausal, is emerging rapidly in East Asia in recent 20 years. Half of the breast cancer patients in Asia are younger than 50 years of age.
- Trial name
- ESCALATE (NCT06225284)
- Testing
- Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg
- Where
- Taiwan
- Volunteers
- 124 people
- Sponsor
- National Taiwan University Hospital
Triple Negative Breast Cancer (TNBC), Early Setting
Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.
CAPTIVATE is a multi-center translational and observational trial, that aims to investigate the impact of the gut microbiome on treatment outcomes in women with untreated, stage I-III Triple Negative undergoing neoadjuvant…
- Trial name
- CAPTIVATE (NCT07551765)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Barts & The London NHS Trust
Triple Negative Breast Cancer
Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis
This study will examine how ctDNA and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.
- Trial name
- NCT05730010
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- Indiana University
Triple-Negative Breast Cancer
DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Both DCb (docetaxel/carboplatin) and EC followed by D (epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been recommended by NCCN guideline.
- Trial name
- NCT03154749
- Testing
- DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Guangdong Provincial People's Hospital
Triple Negative Breast Cancer (TNBC)
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
This clinical trial aims to evaluate the efficacy, safety, and exploratory measures of liposomal doxorubicin and carboplatin combination therapy in the adjuvant setting for early stage triple negative breast cancer (TNBC)…
- Trial name
- NCT05949021
- Testing
- Combination of liposomal doxorubicin
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mridula George, MD
Triple Negative Breast Cancer
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept(1) to assess the clinical utility of ctDNA monitoring combined with 68Ga-FAPI-46-PET-CT imaging upon…
- Trial name
- CUPCAKE (NCT06225505)
- Testing
- ctDNA monitoring, 68Ga-FAPI-46-PET-CT
- Where
- 13 sites in France
- Volunteers
- 450 people
- Sponsor
- Institut Curie
Triple Negative Breast Cancer
CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)
This is an open-label, randomized, window-of-opportunity phase 2 clinical study evaluating the biological activity of preoperative Stereotactic Body RadioTherapy (SBRT) alone (Arm 1), and combined with subcutaneous (SC) followed…
- Trial name
- NCT04807192
- Testing
- stereotactic body radiotherapy, CMP-001
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
TNBC - Triple-Negative Breast Cancer
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer
This study aims to evaluate the efficacy and safety of a PD-1 inhibitor combined with different chemotherapy regimens (PCb-EC and PCb), in order to develop a superior and well-tolerated neoadjuvant therapeutic strategy for…
- Trial name
- NCT07256964
- Testing
- Toripalimab, PCb-EC, PCb
- Volunteers
- 216 people
- Sponsor
- Henan Cancer Hospital
Breast Neoplasms, Triple Negative Breast Neoplasms
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Researchers are looking for new ways to treat types of breast cancer that are both: High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment Early-stage, which means the cancer is…
- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
- Trial name
- NCT06966700
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication
- Where
- 331 sites in United States, Argentina and 39 more
- Volunteers
- 2,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
The purpose of this study is to evaluate the efficacy and safety of Sintilimab plus anlotinib combined with chemotherapy as neoadjuvant therapy in participants who have triple negative breast cancer (TNBC).
- Trial name
- NeoSACT (NCT04877821)
- Testing
- Sintilimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Guangdong Provincial People's Hospital
TNBC - Triple-Negative Breast Cancer
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
Triple-negative breast cancer (TNBC) presents significant challenges due to its limited treatment options and poor efficacy. While neoadjuvant chemotherapy has improved breast-conserving rates and extended survival for TNBC…
- Trial name
- NCT06627712
- Testing
- SBRT+PD-1 Inhibitor + Chemotherapy, PD-1 Inhibitor + Chemotherapy
- Where
- China
- Volunteers
- 318 people
- Sponsor
- West China Hospital